英文発表
【2023】

  1. Hirano T, Tatetsu H, Ueno S, Shichijo T, Furukawa S, Tsujihashi M, Miyakawa T, Shiraishi S, Higuchi Y, Uchiba M, Yasunaga J, Nosaka K, Matsuoka M.
    Significant response of patients with transformed follicular lymphoma with rapid disease progression to CAR-T therapy.
    J Clin Exp Hematop. 26;63(4):266-269, 2023.

【2022】

  1. Uchiba M, Matsuoka M.
    Using weighted harmonic mean for prediction of APTT in the mixing test.
    Thrombosis Update. Volume 8, August 2022, 100114.

  2. Tamanoi D, Saruwatari K, Imamura K, Sato R, Jodai T, Hamada S, Tomita Y, Saeki S, Ueno S, Yonemura Y, Ichiyasu H, Sakagami T.
    A Case of Pembrolizumab-related immune thrombocytopenia in a patient with lung adenocarcinoma treated by radiotherapy: Potential immune-related adverse event elicited by radiation therapy.
    Intern Med. 61:1731-1734, 2022.

【2021】

  1. Ishihara A, Yamauchi T, Ikeda K, Fukuyoshi Y, Yokoyama T, Yonemura Y, Uchiba M, Matsui H.
    Glycosylated ferritin as an improved marker for post-transfusion iron overload.
    Int J Hematol. 2021 Apr;113(4):537-546.

  2. Fujimoto Y, Ueno S, Oda K, Gunda N, Shimomura Y, Nishimura Y, Yamaguchi A, Kuwano A, Ito Y, Baba Y, Nishigaki A, Michiwaki N, Uchino S, Kurogi K, Kawano Y, Matsuoka M, Saito H, Okuno Y, Jono H.
    Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis.
    Cancers (Basel). 13:5674, 2021.

【2019】

  1. Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.
    Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.
    Blood Coagul Fibrinolysis. 30:385-392, 2019.

  2. Nishimura N, Radwan MO, Amano M, Endo S, Fujii E, Hayashi H, Ueno S, Ueno N, Tatetsu H, Hata H, Okamoto Y, Otsuka M, Mitsuya H, Matsuoka M, Okuno Y.
    Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
    Cancer Sci. 110:3275-3287, 2019.

  3. Tatetsu H, Armant M, Wang F, Gao C, Ueno S, Tian X, Federation A, Qi J, Bradner J, Tenen DG, Chai L.
    Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465).
    Exp Hematol. 75:53-63.e11, 2019.

【2018】

  1. Endo S, Nishimura N, Kawano Y, Ueno N, Ueno S, Tatetsu H, Komohara Y, Takeya M, Hata H, Mitsuya H, Masao M, Okuno Y.
    MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells.
    Biophys Res Commun. 507:246-252, 2019.

  2. Tokunaga K, Yamamura A, Ueno S, Kikukawa Y, Yamaguchi S, Hidaka M, Matsuno N, Kawaguchi T, Matsuoka M, Okuno Y.
    Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement.
    Internal Medicine. 57;563-568, 2018.

【2017】

  1. Yamane T, Imai K, Uchiba M, Umezaki N, Yamao T, Kaida T, Nakagawa S, Hashimoto D, Yamashita YI, Chikamoto A, Yoshida N, Baba H.
    Acquired factor V deficiency following transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report.
    Int Cancer Conf J. 2017 Mar 31;6(3):126-130.

  2. Sueta D, Ito M, Uchiba M, Sakamoto K, Yamamoto E, Izumiya Y, Kojima S, Kaikita K, Shinriki S, Hokimoto S, Matsui H, Tsujita K.
    A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan. -usefulness of next generation sequencing-.
    Thromb J. 14;15:8, 2017.

  3. Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H.
    A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
    Haemophilia. 23:59-66, 2017.

  4. Ueno N, Nishimura N, Ueno S, Endo S, Tatetsu H, Hirata S, Hata H, Matsuoka M, Mitsuya H, Okuno Y.
    PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
    Oncogene. 36:4481-4497, 2017.

  5. Nishimura N, Endo S, Ueno S, Ueno N, Tatetsu H, Hirata S, Hata H, Komohara Y, Takeya M, Mitsuya H, Okuno Y.
    A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo.
    Biochem Biophys Res Commun. 486:916-922, 2017.

【2016】

  1. Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M, Mikami Y, Hata H, Okuno Y, Mitsuya H, Nosaka K.
    Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids.
    Int J Hematol. 2016 Jun;103(6):718-23.

  2. Kikukawa Y, Hata H, Ueda M, Yamashita T, Nasu S, Ide K, Ueno S, Ando Y, Mitsuya H, Okuno Y.
    Successful treatment of amyloid light-chain amyloidosis in a Charcot-Marie-Tooth Disease patient with lenalidomide, cyclophosphamide, and dexamethasone.
    Intern Med. 55:2707-12, 2016..